OB/GYN Clinical Alert – October 1, 2008

October 1, 2008

• The Effect of Prior Use of Hormone Therapy on Breast Cancer Survival

  Newcomb and colleagues reported breast cancer mortality in the Collaborative Breast Cancer Study Cohort, a prospective cohort of 12,269 postmenopausal women from Wisconsin, Massachusetts, or New Hampshire.

  Read more

• Bone Loss Is Reversible in Women of All Ages After Discontinuation of Depot Medroxyprogesterone Acetate Injectable Contraception

  Of note, this publication is a review article and not original science. Because of its efficacy and convenience, DMPA has been used by millions of women in the United States and around the world.

  Read more

• Tibolone Fracture Trial

  The lift study (Long-Term Intervention on Fractures with Tibolone) was a randomized, placebo-controlled multicenter trial in 22 countries of tibolone, 1.25 mg, given daily over 3 years.

  Read more

• Müllerian Carcinosarcoma: Unique Neoplasm?

  The objective of this study was to examine and compare the clinical behavior and outcome of uterine carcinosarcoma relative to grade 3 endometrioid carcinoma.

  Read more

• A Comparison of Speculum and Non-speculum Collection Methods of Cervicovaginal Specimens for Fetal Fibronectin Testing

  Fetal fibronectin is now being used in many hospitals to separate out those with preterm contractions (PTCs) who are in true labor from those with contractions who are not (and, therefore, not requiring tocolytics or hospitalization).

  Read more

• Clinical Briefs in Primary Care supplement

  Read more

• Pharmacology Watch: Gender Differences with Anticoagulation Discontinuation

  In this issue: Some women with DVT may stop warfarin after six months; Vytorin and cancer; preventing recurrent stroke; and FDA news.

  Read more